A follow-up study on 6-[18F]Fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progressionin the putamen

Movement Disorders

Volumn 24, Issue 7, 2009, Pages 1009-1015

  Brück, Anna ^a   Aalto, Sargo ^a,b   Rauhala, Elina ^a   Bergman, Jörgen ^a   Marttila, Reijo ^c   Rinne, Juha O ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

6 18F fluoro L dopa; Parkinson's disease; PET; Progression

Indexed keywords

6 FLUORODOPA F 18;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN;

AGED; BRAIN MAPPING; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FUNCTIONAL LATERALITY; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; POSTMORTEM CHANGES; PUTAMEN; TIME FACTORS;

EID: 67651177750     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22484     Document Type: Article

References (25)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
2. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114 (Pt 5):2283-2301.
3. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-382.
4. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50: 140-148.
5. Bergman JHM, Lehikoinen P, Solin O. Electrophilic synthesis of 6-[18F]fluoro-L-dopa, starting from aqueous [18F]-fluoride. J Label Compounds Radiopharm 1994;35:476-477.
6. Namavari M, Bishop A, Satyamurthy N, Bida G, Barrio JR. Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: a high yield synthesis of 6-[18F]Fluoro-L-dopa. Int J Rad Appl Instrum [A] 1992;43:989-996.
7. Bruck A, Aalto S, Nurmi E, Bergman J, Rinne JO. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging 2005;26:891-898.
8. Friston KJHA, Worsley KJ, Poline JP, Frith C, Frackowiak RSJ. Statistical parametric maps in sunctional imaging: a general linear approach. Hum Brain Mapp 1995;2:189-210.
9. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
10. Bruck A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord 2006;21:958-963.
11. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119 (Pt 2):585-591.
12. Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001;16:608-615.
13. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
14. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
15. Forsback S, Niemi R, Marjamaki P, et al. Uptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease. Synapse 2004;51:119-127.
16. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993;34:331-338.
17. Yee RE, Irwin I, Milonas C, et al. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord 2001;16:838-848.
18. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007;30:244-250.
19. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122 (Pt 8):1437-1448.
20. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
21. Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J Neural Transm 2002;109:1433-1443.
22. Ferguson LW, Rajput ML, Muhajarine N, Shah SM, Rajput A. Clinical features at first visit and rapid disease progression in Parkinson's disease. Parkinsonism Relat Disord 2008;14:431-435.
23. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-1615.
24. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999;52:932-937.
25. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.